Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of single rising doses of survodutide in healthy men
NCT03175211Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2017
- Primary completion
- Feb 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in obesity comparing BI 456906 with Placebo (2 arms). Primary endpoint: Number of subjects with drug-related adverse events up to 672 hours. Started Jun 2017; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03175211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03175211.